Penumbra Competitive Intelligence & Landscape

Penumbra specializes in both Neuro and Vascular healthcare technologies. A featured product is THUNDERBOLT®, which is the latest Penumbra® CAVT™ platform, and the first and only cleared technology to utilize modulated aspiration for stroke thrombectomy [https://penumbrainc.com/]. The company's comprehensive product portfolio is designed to support healthcare providers, hospitals, and clinics across more than 100 countries globally [https://www.penumbrainc.com/investors/].

With a workforce exceeding 4,700 employees, Penumbra is dedicated to transforming patient care through innovative therapies [https://www.penumbrainc.com/about-us/]. Their mission is to improve patient outcomes by developing pioneering medical devices and solutions. The company's commitment to saving patient lives is a core value that inspires their individual and collective efforts [https://www.penumbrainc.com/about-us/careers/].

Penumbra serves a target market of healthcare providers, hospitals, and clinics worldwide, offering advanced solutions in areas like neuro thrombectomy, neuro embolization, peripheral thrombectomy, and vascular access [https://penumbrainc.com/]. The company emphasizes its impact on patient lives through various success stories and continues to invite professionals to join their purpose-driven team [https://penumbrainc.com/].

Within their product lines, Penumbra features specialized platforms like THUNDERBOLT®, which is the first and only cleared technology to utilize modulated aspiration for stroke thrombectomy, part of the Penumbra® CAVT™ platform. The company also highlights its Interventional Cardiology Complete Platform, which includes Lightning Flash 3.0 with next-gen CAVT™ software for venous thrombus removal and treatment of pulmonary embolism (PE), along with the CAT™16 aspiration catheter [https://www.penumbrainc.com/penumbra-cardiology-platform/]. Additionally, the BENCHMARK BMX Family of catheters supports neurovascular intervention by providing access and arch support for the introduction of interventional devices [https://www.penumbrainc.com/access-deliver-pack/].

While specific pricing plans for individual products are not publicly disclosed on their website, Penumbra does acknowledge that amounts billed on invoices may reflect discounts or volume rebates on the products listed [https://www.penumbrainc.com/terms-and-conditions/]. Information regarding potential reimbursement values for certain procedures utilizing Penumbra devices is available. For instance, the 2025 National DRG Payment for "Craniotomy with Major Device Implant or Acute CNS PDX with MCC or Chemotherapy Implant or Epilepsy with Neurostimulator" is listed at $40,600, with other related procedures ranging from $27,055 to $31,827 [https://www.penumbrainc.com/pdf/neuro-reimbursement-guide/]. This suggests that the cost of their devices is often integrated into broader procedural reimbursement frameworks.

There is no explicit mention of free vs. paid features, subscription tiers, or recent pricing changes directly on Penumbra's website. The company operates by providing medical devices that are likely purchased by healthcare providers and hospitals, with costs subsequently incorporated into patient care and billed through medical and insurance channels.

Penumbra consistently posts open positions on platforms like the Lever job board, indicating a continuous need for new talent across various departments [https://www.penumbrainc.com/au/about-us/careers/]. Notably, the company is seeking to fill roles in engineering, as highlighted by a recruiter responsible for hiring top talent in Alameda and Roseville, CA [https://www.penumbrainc.com/employee-spotlight-dexter-whack/]. Additionally, there's a strong emphasis on strengthening their production teams, with a senior recruiter dedicated to attracting top-tier talent for these roles, as well as customer service [https://www.penumbrainc.com/employee-spotlight-maria-r-contreras/].

The company's hiring patterns signal a strategic focus on both innovation and manufacturing, essential for developing and producing their novel healthcare technologies. For instance, in Costa Rica, Penumbra is actively recruiting for production operators, requiring experience in clean room environments, underscoring their commitment to quality manufacturing [https://www.penumbrainc.com/cr/]. These ongoing recruitment efforts across different regions and departments indicate a healthy expansion phase and a drive to meet increasing demand for their medical devices.

While specific layoff information is not available from the provided sources, the consistent messaging about growth and open positions strongly suggests a period of expansion rather than contraction.

Penumbra encourages prospective employees to explore their careers page for open positions and provides clear contact information for verifying interview requests or job offers, emphasizing transparency in its hiring process [https://www.penumbrainc.com/about-us/careers/], [https://www.penumbrainc.com/contact-us/]. This robust hiring activity aligns with their stated purpose of innovating with purpose to help as many people as possible globally.

Penumbra consistently shows quarter-over-quarter growth, with first-quarter 2026 revenue reaching $374.8 million, a 15.6% increase from the first quarter of 2025 [https://www.penumbrainc.com/penumbra-inc-reports-first-quarter-2026-financial-results/]. In the first quarter of 2025, revenue was $324.1 million, a 16.3% increase from the first quarter of 2024 [https://www.penumbrainc.com/penumbra-inc-reports-first-quarter-2025-financial-results/]. Second-quarter 2025 revenue stood at $339.5 million, an increase of 13.4% compared to the second quarter of 2024 [https://www.penumbrainc.com/penumbra-inc-reports-second-quarter-2025-financial-results/]. Third-quarter 2025 revenue was $354.7 million, reflecting a 17.8% increase over the third quarter of 2024 [https://www.penumbrainc.com/penumbra-inc-reports-third-quarter-2025-financial-results/].

The company is recognized as the world's leading thrombectomy company, with its innovative THUNDERBOLT® platform being the first and only cleared technology to utilize modulated aspiration for stroke thrombectomy [https://penumbrainc.com/].

Penumbra's consistent revenue growth and leadership in the thrombectomy market highlight its strong financial health and strategic focus on advancing healthcare technologies globally [https://www.penumbrainc.com/investors/].

Penumbra frequently engages with the financial community, presenting at significant investor events like the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, and the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 6, 9. These engagements highlight the company's financial performance and strategic direction.

The company is also deeply involved in the medical education sphere, offering the Penumbra Physician In Training (PIT) Program, which includes various courses for vascular interventional trainees. This program encompasses participation in society events such as Baylor Fellows Bootcamp 2026, UCLA Moore Course, Vascular Bootcamp 2026, PICS 2026, Penumbra Base Camp 2026, EVS 2026, MVSS 2026, SVM 2026, WVS 2026, SIR Residency Practicum 2026, PERT Symposium 2026, VEINS VIVA 2026, and TCT 2026, alongside their own Penumbra PIT Course 202 4.

Furthermore, Penumbra shares new clinical data and research at prominent medical conferences. For instance, new data from the STRIKE-PE and STRIDE studies were presented at the Society of Interventional Radiology (SIR) Annual Scientific Meeting from March 29th through April 2nd, 2025 5. They also participate in events like ISET 2025, where their research on venous clot management and acute limb ischemia outcomes is presented 7. The company encourages healthcare professionals to register for their educational events 8. Additional upcoming events include 3C 2026, SNIS & Fellows Course 2026, CNS 2026, and SVIN 2026 3.